CD133 has been used to enrich for cells with tumor-initiating ability from a variety of human solid tumors from the brain, prostate, liver, breast and colon [42], but there are also studies that question the value of CD133 as a putative CSC marker, particularly in colon cancer and melanoma [16]. Here, PROM1 is linked to neoplasm.